Literature DB >> 10810208

Pharmacodynamics and pharmacokinetics of levofloxacin.

C H Nightingale1, E M Grant, R Quintiliani.   

Abstract

Principles of antibiotic pharmacodynamics include factors that are important for effective eradication of bacteria as well as the suppression of resistance. For effective eradication of bacteria and a good clinical outcome, a ratio for the area under the plasma concentration-time curve relative to the minimum inhibitory concentration (AUC/MIC) of greater than 100 is needed for gram-negative organisms, and a level of greater than 30 is required for gram-positive organisms. Pharmacodynamic principles can also be used to devise the optimal administration regimen for specific antimicrobial agents. Pharmacodynamic analysis of the activity of levofloxacin against Streptococcus pneumoniae revealed that, 99% of the time, actual hospitalized patients achieve an AUC/MIC of greater than 30. This indicates that levofloxacin will be very effective in treating S. pneumoniae infections in the majority of patients. Cost of treatment is an increasing concern voiced by healthcare providers and users alike. This has led to a much greater emphasis placed upon the cost of individual drugs used in the management of infections. However, when evaluating the cost of an antibiotic, it is extremely important that not only are the direct acquisition costs assessed, but consideration also given to other aspects incurring a financial burden, such as drug preparation cost, supplies, costs of treating adverse events or any treatment failures. It is only by having such a full assessment of costs that realistic financial comparisons can be made between different antibiotics.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10810208     DOI: 10.1159/000048487

Source DB:  PubMed          Journal:  Chemotherapy        ISSN: 0009-3157            Impact factor:   2.544


  16 in total

1.  Influence of Pharmacokinetic and Pharmacodynamic Principles on Antibiotic Selection.

Authors:  George G. Zhanel
Journal:  Curr Infect Dis Rep       Date:  2001-02       Impact factor: 3.725

2.  The disposition kinetics, urinary excretion and dosage regimen of ciprofloxacin in buffalo calves (Bubalus bubalis).

Authors:  S P Saini; A K Srivastava
Journal:  Vet Res Commun       Date:  2001-12       Impact factor: 2.459

3.  Pharmacokinetic disposition of subcutaneously administered enrofloxacin in goats.

Authors:  S Ramesh; G S Rao; J K Malik
Journal:  Vet Res Commun       Date:  2002-10       Impact factor: 2.459

4.  A randomized, open, multicenter clinical study on the short course of intravenous infusion of 750 mg of levofloxacin and the sequential standard course of intravenous infusion/oral administration of 500 mg of levofloxacin for treatment of community-acquired pneumonia.

Authors:  Tiemei Zhao; Liang-An Chen; Ping Wang; Guizhen Tian; Feng Ye; Huili Zhu; Bei He; Baiying Zhang; Changzhou Shao; Zhijun Jie; Xiwen Gao; Dongxia Wang; Weidong Song; Zhijie Pan; Jin Chen; Xingyi Zhang; Zhancheng Gao; Ping Chen; Youning Liu
Journal:  J Thorac Dis       Date:  2016-09       Impact factor: 2.895

Review 5.  Antimicrobial therapy in critically ill patients: a review of pathophysiological conditions responsible for altered disposition and pharmacokinetic variability.

Authors:  Federico Pea; Pierluigi Viale; Mario Furlanut
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 6.447

Review 6.  Levofloxacin: a review of its use in the treatment of bacterial infections in the United States.

Authors:  Katherine F Croom; Karen L Goa
Journal:  Drugs       Date:  2003       Impact factor: 9.546

Review 7.  New developments in antibacterial choice for lower respiratory tract infections in elderly patients.

Authors:  Anna Maria Ferrara; Anna Maria Fietta
Journal:  Drugs Aging       Date:  2004       Impact factor: 3.923

Review 8.  Cost-effective approaches to the treatment of community-acquired pneumonia in the era of resistance.

Authors:  Joseph L Kuti; Blair Capitano; David P Nicolau
Journal:  Pharmacoeconomics       Date:  2002       Impact factor: 4.981

9.  Levofloxacin disposition in cerebrospinal fluid in patients with external ventriculostomy.

Authors:  Federico Pea; Federica Pavan; Ennio Nascimben; Claudio Benetton; Pier Giorgio Scotton; Alberto Vaglia; Mario Furlanut
Journal:  Antimicrob Agents Chemother       Date:  2003-10       Impact factor: 5.191

Review 10.  Levofloxacin: an updated review of its use in the treatment of bacterial infections.

Authors:  Miriam Hurst; Harriet M Lamb; Lesley J Scott; David P Figgitt
Journal:  Drugs       Date:  2002       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.